Outcome After Out of Hospital Cardiac Arrest in Bern, Switzerland
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Nov 28, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the outcomes of patients who have experienced a sudden cardiac arrest outside of a hospital in Bern, Switzerland, between 2015 and 2018. Cardiac arrest is a serious condition where the heart stops beating, and it can lead to death if not treated quickly. The trial specifically looks at the survival rates and brain function of these patients, especially focusing on a treatment called extracorporeal membrane oxygenation (ECMO), also known as eCPR, which can help maintain blood flow and oxygen to the body during resuscitation efforts.
If you or someone you know had a cardiac arrest in Bern during the years 2015-2017, you might be eligible to participate in this study. The researchers are looking at all cases of out-of-hospital cardiac arrest from that time, except for patients who have previously chosen not to be part of studies. Participants can expect that their medical data will be reviewed to help understand how effective the eCPR treatment is, providing valuable insights that could improve care for future patients experiencing cardiac arrest.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All OHCA in the region of Bern, Switzerland in the year 2015-2017
- Exclusion Criteria:
- • if patient has previously declined to be included in a study (advance directive)
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Robert Greif, Prof., M.D.
Study Chair
University Hospital Bern, Bern, Switzerland
Sabine Nabecker, M.D.
Principal Investigator
University Hospital Bern, Bern, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials